NasdaqCM - Delayed Quote USD

Turnstone Biologics Corp. (TSBX)

0.3127

-0.0074

(-2.31%)

At close: June 2 at 4:00:00 PM EDT

Turnstone Biologics Corp. Reports First Quarter 2025 Financial Results and Provides Recent Corporate Highlights

SAN DIEGO, May 08, 2025 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq-CM: TSBX), a biotechnology company historically focused on the development of a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (“Selected TIL”) therapy, today reported financial results for the first quarter ended March 31, 2025, and provided recent corporate updates. Corporate Updates In January 2025, Turnstone ma

GlobeNewswire 25 days ago

TSBX
-2.31%
Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2024 Financial Results

SAN DIEGO, March 28, 2025 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a biotechnology company historically focused on the development of a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (“Selected TIL”) therapy, today announced its financial results for the fourth quarter and full year ended December 31, 2024, and provided recent corporate updates. Corporate Updates In Nove

GlobeNewswire 2 months ago

TSBX
-2.31%
Turnstone Biologics Corp. (TSBX) Upgraded to Buy: What Does It Mean for the Stock?

Turnstone Biologics Corp. (TSBX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks 3 months ago

TSBX
-2.31%
Amgen obesity drug on hold; Regeneron sets first dividend

Elsewhere, cell therapy developer Turnstone Biologics announced a second round of layoffs and plans to explore “strategic alternatives.”

BioPharma Dive 3 months ago

AMGN

REGN

TSBX
-2.31%
Turnstone Biologics Announces Plans to Explore Strategic Alternatives

SAN DIEGO, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX) today announced that it has completed an assessment of its business and operations, including the status of its program, resources, and capabilities. The Company has made the determination to discontinue all clinical studies evaluating TIDAL-01 and halt further development of the program. As a result, Turnstone’s management and its Board of Directors have initiated a process to ex

GlobeNewswire 3 months ago

TSBX
-2.31%
Turnstone Biologics Corp. Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights

Portfolio Prioritization and Corporate Restructuring Extends Cash Runway into 2Q 2026SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today reported financial results for the third quarter ended September 30, 2024, and provided recen

GlobeNewswire 6 months ago

TSBX
-2.31%
Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Turnstone’s next-generation Selected TIL technology is designed to selectively expand the most potent tumor-reactive T cells for treatment of solid tumors Results further support the continued clinical advancement of TIDAL-01, currently being evaluated in Phase 1 trials SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with sol

GlobeNewswire 6 months ago

TSBX
-2.31%
Turnstone Biologics Streamlines Operations and Leadership

Turnstone Biologics Corp. ( (TSBX) ) has shared an announcement. Turnstone Biologics Corp. has initiated a strategic reorganization to hone its focus on advancing its Phase 1 TIDAL-01 program, resulting in a 60% reduction in its workforce and a reshuffling of its leadership team. These changes are designed to streamline operations, extend the company’s financial runway into the second quarter of 2026, and enhance shareholder value. The restructuring includes severance and outplacement support fo

TipRanks 7 months ago

TSBX
-2.31%
FDA clears Roche breast cancer drug; Turnstone lays off 60% of staff

Itovebi is part of a push by Roche to make new inroads in breast cancer. Elsewhere, Turnstone is trimming preclinical research and Gritstone bio is working on a bankruptcy deal.

BioPharma Dive 7 months ago

TSBX
-2.31%

PFE

ROG.SW
Turnstone Biologics Announces Strategic Restructuring to Prioritize Portfolio and Extend Financial Runway

Realigning resources to focus on clinical advancement of Selected TIL therapyReducing employee headcount by approximately 60%Streamlining operations with cash runway expected to extend into 2Q 2026 SAN DIEGO, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected

GlobeNewswire 7 months ago

TSBX
-2.31%
Turnstone Biologics Corp. Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights

Announced positive initial data from Phase 1 trial of TIDAL-01 in metastatic colorectal cancer including a complete response in one of the four patients reported Cash position expected to fund operations into 3Q 2025 SAN DIEGO, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating ly

GlobeNewswire 9 months ago

TSBX
-2.31%
Turnstone Biologics Corp. Reports Positive Initial Data from Phase 1 Trial of TIDAL-01 in Metastatic Colorectal Cancer

Overall response rate (“ORR”) of 25% and 50% disease control rate ("DCR") observed in first four evaluable patients treated with TIDAL-01 with advanced CRC Complete response achieved in heavily pre-treated late line patient with progression free survival extending beyond one year Favorable tolerability profile and demonstrated manufacturing successProduct characterization and translational data support biological hypothesis for Selected TILs SAN DIEGO, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Turnstone

GlobeNewswire 9 months ago

TSBX
-2.31%
Turnstone Biologics Corp. (TSBX): This Penny Stock is a ‘Strong Buy’ According to Analysts

We recently compiled a list of the 10 Best New Penny Stocks To Buy Now. In this article, we are going to take a look at where Turnstone Biologics Corp. (NASDAQ:TSBX) stands against the other new penny stocks. Fears of a US recession are growing, sending stock markets down, and investors around the world are on […]

Insider Monkey 9 months ago

TSBX
-2.31%
Can Turnstone Biologics (NASDAQ:TSBX) Afford To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Simply Wall St. 10 months ago

TSBX
-2.31%

Performance Overview

Return	TSBX	S&P 500 (^GSPC)
YTD	-37.08%	+0.92%
1-Year	-88.02%	+12.48%
3-Year	-97.26%	+42.12%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Turnstone Biologics Corp. (TSBX)

Turnstone Biologics Corp. Reports First Quarter 2025 Financial Results and Provides Recent Corporate Highlights

Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2024 Financial Results

Turnstone Biologics Corp. (TSBX) Upgraded to Buy: What Does It Mean for the Stock?

Amgen obesity drug on hold; Regeneron sets first dividend

Turnstone Biologics Announces Plans to Explore Strategic Alternatives

Turnstone Biologics Corp. Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights

Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Turnstone Biologics Streamlines Operations and Leadership

FDA clears Roche breast cancer drug; Turnstone lays off 60% of staff

Turnstone Biologics Announces Strategic Restructuring to Prioritize Portfolio and Extend Financial Runway

Turnstone Biologics Corp. Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights

Turnstone Biologics Corp. Reports Positive Initial Data from Phase 1 Trial of TIDAL-01 in Metastatic Colorectal Cancer

Turnstone Biologics Corp. (TSBX): This Penny Stock is a ‘Strong Buy’ According to Analysts

Can Turnstone Biologics (NASDAQ:TSBX) Afford To Invest In Growth?

Performance Overview